60
Participants
Start Date
September 30, 2008
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Lenalidomide
Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
Rituximab
Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
The University of Texas M.D. Anderson Cancer Center, Houston
Collaborators (1)
Celgene Corporation
INDUSTRY
M.D. Anderson Cancer Center
OTHER